HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
HLA class I-restricted MYD88 L265P-derived peptides as specific targets for lymphoma immunotherapy
Authors
Keywords
-
Journal
OncoImmunology
Volume 6, Issue 3, Pages e1219825
Publisher
Informa UK Limited
Online
2016-12-25
DOI
10.1080/2162402x.2016.1219825
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- High frequency of MYD88 mutations in vitreoretinal B-cell lymphoma: a valuable tool to improve diagnostic yield of vitreous aspirates
- (2015) I. Bonzheim et al. BLOOD
- The antigenic landscape of multiple myeloma: mass spectrometry (re)defines targets for T-cell-based immunotherapy
- (2015) S. Walz et al. BLOOD
- MYD88L265P andCXCR4mutations in lymphoplasmacytic lymphoma identify cases with high disease activity
- (2015) Janine Schmidt et al. BRITISH JOURNAL OF HAEMATOLOGY
- Targeting immune checkpoints in lymphoma
- (2015) Stephen M. Ansell CURRENT OPINION IN HEMATOLOGY
- Phase I study of the anti-CD74 monoclonal antibody milatuzumab (hLL1) in patients with previously treated B-cell lymphomas
- (2015) Peter Martin et al. LEUKEMIA & LYMPHOMA
- Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma
- (2015) Wyndham H Wilson et al. NATURE MEDICINE
- NY-ESO-1–specific TCR–engineered T cells mediate sustained antigen-specific antitumor effects in myeloma
- (2015) Aaron P Rapoport et al. NATURE MEDICINE
- PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma
- (2015) Stephen M. Ansell et al. NEW ENGLAND JOURNAL OF MEDICINE
- HLA ligandomics identifies histone deacetylase 1 as target for ovarian cancer immunotherapy
- (2015) Janet Kerstin Peper et al. OncoImmunology
- Activation of lymphoma-associated MyD88 mutations via allostery-induced TIR-domain oligomerization
- (2014) M. Avbelj et al. BLOOD
- Mutations in TLR/MYD88 pathway identify a subset of young chronic lymphocytic leukemia patients with favorable outcome
- (2014) A. Martinez-Trillos et al. BLOOD
- Orchestrating immune check-point blockade for cancer immunotherapy in combinations
- (2014) Jose Luis Perez-Gracia et al. CURRENT OPINION IN IMMUNOLOGY
- Genomic and bioinformatic profiling of mutational neoepitopes reveals new rules to predict anticancer immunogenicity
- (2014) Fei Duan et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial
- (2014) Caroline Robert et al. LANCET
- Mapping the HLA ligandome landscape of acute myeloid leukemia: a targeted approach toward peptide-based immunotherapy
- (2014) C Berlin et al. LEUKEMIA
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- HLA ligandome analysis identifies the underlying specificities of spontaneous antileukemia immune responses in chronic lymphocytic leukemia (CLL)
- (2014) Daniel J. Kowalewski et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Activation of TAK1 by MYD88 L265P drives malignant B-cell Growth in non-Hodgkin lymphoma
- (2014) S M Ansell et al. Blood Cancer Journal
- Prevalence and clinical significance of the MYD88 (L265P) somatic mutation in Waldenstrom's macroglobulinemia and related lymphoid neoplasms
- (2013) M. Varettoni et al. BLOOD
- Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)
- (2013) J. Greiner et al. BLOOD
- MYD88 L265P in Waldenstrom macroglobulinemia, immunoglobulin M monoclonal gammopathy, and other B-cell lymphoproliferative disorders using conventional and quantitative allele-specific polymerase chain reaction
- (2013) L. Xu et al. BLOOD
- Identification of HLA ligands and T-cell epitopes for immunotherapy of lung cancer
- (2013) Anneke Neumann et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Evolution and Impact of Subclonal Mutations in Chronic Lymphocytic Leukemia
- (2013) Dan A. Landau et al. CELL
- Tumor Exome Analysis Reveals Neoantigen-Specific T-Cell Reactivity in an Ipilimumab-Responsive Melanoma
- (2013) Nienke van Rooij et al. JOURNAL OF CLINICAL ONCOLOGY
- Nivolumab plus Ipilimumab in Advanced Melanoma
- (2013) Jedd D. Wolchok et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia
- (2012) J. Greiner et al. BLOOD
- Ipilimumab in Combination With Paclitaxel and Carboplatin As First-Line Treatment in Stage IIIB/IV Non–Small-Cell Lung Cancer: Results From a Randomized, Double-Blind, Multicenter Phase II Study
- (2012) Thomas J. Lynch et al. JOURNAL OF CLINICAL ONCOLOGY
- Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival
- (2012) Steffen Walter et al. NATURE MEDICINE
- MYD88 L265P Somatic Mutation in Waldenström's Macroglobulinemia
- (2012) Steven P. Treon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
- (2012) Suzanne L. Topalian et al. NEW ENGLAND JOURNAL OF MEDICINE
- Durable Complete Responses in Heavily Pretreated Patients with Metastatic Melanoma Using T-Cell Transfer Immunotherapy
- (2011) S. A. Rosenberg et al. CLINICAL CANCER RESEARCH
- Promiscuous survivin peptide induces robust CD4+ T-cell responses in the majority of vaccinated cancer patients
- (2011) Melanie Widenmeyer et al. INTERNATIONAL JOURNAL OF CANCER
- Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia
- (2011) Xose S. Puente et al. NATURE
- Analysis of the coding genome of diffuse large B-cell lymphoma
- (2011) Laura Pasqualucci et al. NATURE GENETICS
- A flow cytometry-based assay to assess minute frequencies of CD8+ T cells by their cytolytic function
- (2010) Jonas Stanke et al. JOURNAL OF IMMUNOLOGICAL METHODS
- Treatment of patients with fludarabine-refractory chronic lymphocytic leukemia: need for new treatment options
- (2010) Apostolia-Maria Tsimberidou et al. LEUKEMIA & LYMPHOMA
- Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
- (2010) Susanne M Rittig et al. MOLECULAR THERAPY
- Oncogenically active MYD88 mutations in human lymphoma
- (2010) Vu N. Ngo et al. NATURE
- Accurate approximation method for prediction of class I MHC affinities for peptides of length 8, 10 and 11 using prediction tools trained on 9mers
- (2008) C. Lundegaard et al. BIOINFORMATICS
- Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials
- (2008) Hyun Jun Park et al. BRITISH JOURNAL OF HAEMATOLOGY
- Stromal Gene Signatures in Large-B-Cell Lymphomas
- (2008) G. Lenz et al. NEW ENGLAND JOURNAL OF MEDICINE
- NetMHC-3.0: accurate web accessible predictions of human, mouse and monkey MHC class I affinities for peptides of length 8–11
- (2008) Claus Lundegaard et al. NUCLEIC ACIDS RESEARCH
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now